AstraZeneca Sees Malaria Venture Pact As Template For Branching Out Assets Into New Areas
This article was originally published in PharmAsia News
Executive Summary
In what it calls a template for future agreements that might further leverage its library of compounds, AstraZeneca has agreed to give Medicines for Malaria Venture a no-charge look at about 500,000 proprietary compounds to see if they have potential in Plasmodium falciparum malaria